nach oben

Erschienen in:

01.12.2014 | Neurology and Preclinical Neurological Studies - Review Article

Does CSF p-tau₁₈₁ help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

Erschienen in: Journal of Neural Transmission | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the clinical importance of cerebrospinal fluid (CSF) phosphorylated tau 181 (p-tau₁₈₁) in mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other dementias, more specifically: frontotemporal degeneration (FTD), dementia with Lewy bodies (DLB), vascular dementia (VaD) and Parkinson’s disease (PD) with dementia (PDD). Fifty eligible articles were identified by search of databases including PubMed, EMBASE, Elsevier, Springer Link and the Cochrane Library, up to December 2013. The random effects model was used to calculate the standardized mean difference (SMD) with corresponding 95 % CI by STATA 9.0 software. The subgroup analyses were made on the methods or PD with dementia. We found that CSF p-tau₁₈₁ concentrations were significantly higher in AD compared to MCI [SMD: 0.61, 95 % CI: (0.46, 0.76), z = 8.07, P < 0.001], FTD [SMD: 1.23, 95 % CI: (0.89, 1.56), z = 7.19, P < 0.001], DLB [SMD: 1.08, 95 % CI: (0.80, 1.37), z = 7.41, P < 0.001], PDD [SMD: 1.05, 95 % CI: (0.02, 2.07), z = 2.00, P = 0.045] and VaD [SMD: 1.28, 95 % CI: (0.68, 1.88), z = 4.19, P < 0.001]. Results from this meta-analysis implied that CSF p-tau₁₈₁ is a good biomarker for discriminating Alzheimer’s disease from other dementias and mild cognitive impairment.

Alexopoulos P, Guo LH, Kratzer M et al (2011) Impact of SORL1 single nucleotide polymorphisms on Alzheimer’s disease cerebrospinal fluid markers. Dement Geriatr Cognit Disord 32:164–170CrossRef

Apostolova LG, Hwang KS, Andrawis JP et al (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31(8):1284–1303PubMedCentralPubMedCrossRef

Bibl M, Mollenhauer B, Esselmann H et al (2008) Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cognit Disord 25(3):256–265CrossRef

Blasko I, Lederer W, Oberbauer H et al (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cognit Disord 21(1):9–15CrossRef

Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1(2):213–225PubMedCentralPubMedCrossRef

Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2:605–613PubMedCrossRef

Blennow K, Wallin A, Hager O (1993) Low frequency of postlumbar puncture headache in demented patients. Acta Neurol Scand 88:221–223PubMedCrossRef

Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403PubMedCrossRef

Blom ES, Giedraitis V, Zetterberg H et al (2009) Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cognit Disord 27(5):458–464CrossRef

Borroni B, Malinverno M, Gardoni F et al (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71(22):1796–1803PubMedCrossRef

Borroni B, Gardoni F, Parnetti L et al (2009) Pattern of tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30:34–40PubMedCrossRef

Bouwman FH, van der Flier WM, Schoonenboom NS et al (2007) Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 69(10):1006–1011PubMedCrossRef

Chui HC, Victoroff JI, Margolin D et al (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 42:473–480PubMedCrossRef

Cohen J (1992) A power primer. Psychol Bull 112:155–159PubMedCrossRef

Cummings JL (1988) Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1(1):24–36PubMedCrossRef

de Jong D, Jansen RW, Kremer BP, Verbeek MM (2006) Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61(7):755–758PubMedCrossRef

Emre M (2003) Dementia associated with Parkinson’s disease. Lancet Neurol 2(4):229–237PubMedCrossRef

Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707PubMedCrossRef

Engelborghs S, Maertens K, Vloeberghs E et al (2006) Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 48:286–295PubMedCrossRef

Exalto LG, van der Flier WM, Scheltens P, Biessels GJ (2010) Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic. J Am Geriatr Soc 58(7):1318–1321PubMedCrossRef

Frank RA, Galasko D, Hampel H et al (2003) Biological markers for therapeutic trials in Alzheimer’s disease. Neurobiol Aging 24(4):521–536PubMedCrossRef

Gabelle A, Roche S, Gény C et al (2011) Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis 26(3):553–563PubMed

Galimberti D, Venturelli E, Fenoglio C et al (2008) Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer’s disease and frontotemporal lobar degeneration. J Neurol 255:539–544PubMedCrossRef

Habert MO, de Souza LC, Lamari F et al (2010) Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 37(3):589–593PubMedCrossRef

Hampel H, Mitchell A, Blennow K et al (2004) Core biological marker candidates of Alzheimer’s disease—perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 111:247–272PubMedCrossRef

Hampel H, Blennow K, Shaw LM et al (2010) Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 45:30–40PubMedCentralPubMedCrossRef

Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234PubMedCrossRef

Henneman WJ, Vrenken H, Barnes J et al (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73(12):935–940PubMedCentralPubMedCrossRef

Herbert MK, Aerts MB, Kuiperij HB et al (2013) Addition of MHPG to Alzheimer’s disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer’s disease but not other dementias. Alzheimers Dement. doi:10.1016/j.jalz.2013.05.1775 PubMed

Ibach B, Binder H, Dragon M et al (2006) Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 27(9):1202–1211PubMedCrossRef

Irwin DJ, White MT, Toledo JB et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72(4):587–598PubMedCentralPubMedCrossRef

Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193–1199PubMedCentralPubMedCrossRef

Jellinger KA (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol 91:219–220PubMedCrossRef

Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270–279PubMedCrossRef

Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115(4):427–436PubMedCrossRef

Jia JP, Meng R, Sun YX et al (2005) Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer’s disease and vascular dementia. Neurosci Lett 383:12–16PubMedCrossRef

Jicha GA, Abner EL, Schmitt FA (2012) Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(3):622.e1–622.e16CrossRef

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM (2012) Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer’s disease. Methods 56(4):484–493PubMedCrossRef

Kasuga K, Tokutake T, Ishikawa A et al (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81(6):608–610PubMedCrossRef

Lanari A, Parnetti L (2009) Cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment: 4-year follow-up in a routine clinical setting. Sci World J 9:961–966CrossRef

Le Bastard N, Van Buggenhout M, De Leenheir E et al (2007) Low specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer’s disease from vascular dementia. J Gerontol A Biol Sci Med Sci 62:923–924PubMedCrossRef

Lewczuk P, Beck G, Ganslandt O et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4PubMedCrossRef

Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293PubMedCrossRef

McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedCrossRef

McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65:1863–1872PubMedCrossRef

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMedCrossRef

Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80:966–975PubMedCrossRef

Mollenhauer B, Bibl M, Wiltfang J et al (2006) Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1–40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44(2):192–195PubMedCrossRef

Mouton-Liger F, Paquet C, Dumurgier J et al (2012) Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer’s disease. Biol Psychiatry 71:829–835PubMedCrossRef

Mulugeta E, Londos E, Ballard C et al (2011) CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 82(2):160–164PubMedCrossRef

Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMedCrossRef

Nettiksimmons J, Harvey D, Brewer J et al (2010) Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging 31(8):1419–1428PubMedCentralPubMedCrossRef

Noguchi-Shinohara M, Tokuda T, Yoshita M et al (2009) CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer’s disease. Brain Res 1251:1–6PubMedCrossRef

Okonkwo OC, Alosco ML, Griffith HR et al (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67(6):688–696PubMedCentralPubMedCrossRef

Parnetti L, Lanari A, Silvestrelli G et al (2006) Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev 127(2):129–132PubMedCrossRef

Parnetti L, Tiraboschi P, Lanari A et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64(10):850–855PubMedCrossRef

Randall C, Mosconi L, de Leon M et al (2013) Cerebrospinal fluid biomarkers of Alzheimer’s disease in healthy elderly. Front Biosci 18:1150–1173CrossRef

Ravaglia S, Bini P, Sinforiani E et al (2008) Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia. Neurol Sci 29:417–423PubMedCrossRef

Regeniter A, Kuhle J, Baumann T et al (2012) Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods 56(4):494–499PubMedCrossRef

Riepe MW, Karl J, Tumani H, von Arnim CA (2010) Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment. Dement Geriatr Cognit Disord 30(2):93–100CrossRef

Roman GC, Tatemichi TK, Erkinjutti T et al (1993) Vascular dementia: diagnostic criteria for research studies-report of the NINDSAIREN International Workshop. Neurology 43(2):250–260PubMedCrossRef

Schmand B, Eikelenboom P, van Gool WA et al (2011) Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer’s disease in younger and older age cohorts. J Am Geriatr Soc 59(9):1705–1710PubMedCrossRef

Schott JM, Bartlett JW, Barnes J et al (2010) Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 31(8):1452–1462PubMedCentralPubMedCrossRef

Seppälä TT, Koivisto AM, Hartikainen P et al (2011) Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis 25(4):583–594PubMed

Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65(4):403–413PubMedCentralPubMedCrossRef

Sjögren M, Davidsson P, Tullberg M et al (2001) Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 70:624–630PubMedCentralPubMedCrossRef

Sjögren M, Davidsson P, Wallin A et al (2002) Decreased CSF-beta-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta amyloid induced by disparate mechanisms. Dement Geriatr Cognit Disord 13:112–118CrossRef

Sluimer JD, Bouwman FH, Vrenken H et al (2010) Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 31(5):758–764PubMedCrossRef

Solé-Padullés C, Lladó A, Bartrés-Faz D et al (2011) Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer’s disease continuum. Psychiatry Res 192(3):140–146PubMedCrossRef

Spies PE, Slats D, Sjögren JM et al (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer’s disease from non-Alzheimer’s dementia. Curr Alzheimer Res 7(5):470–476PubMedCrossRef

Sundelöf J, Sundström J, Hansson O et al (2010) Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer’s disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 21(2):471–478PubMed

Thorsell A, Bjerke M, Gobom J et al (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 1362:13–22PubMedCrossRef

Tomlinson BE, Blessed G, Roth M (1970) Observations on brains of demented old people. J Neurol Sci 11:205–242PubMedCrossRef

Tosun D, Schuff N, Truran-Sacrey D et al (2010) Relations between brain tissue loss, CSF biomarkers and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 31(8):1340–1354PubMedCentralPubMedCrossRef

van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76(Suppl 5):v2–v7PubMedCentralPubMedCrossRef

van Harten AC, Kester MI, Visser PJ et al (2011) Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 49(3):353–366PubMed

Verwey NA, Kester MI, van der Flier WM et al (2010) Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20(2):445–452PubMed

Wada-Isoe K, Kitayama M, Nakaso K et al (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260:33–37PubMedCrossRef

Waldemar G, Dubois B, Emre M et al (2007) Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14:e1–e26PubMedCrossRef

Wennström M, Londos E, Minthon L et al (2012) Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis 29(1):125–132PubMed

Westin K, Buchhave P, Nielsen H et al (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer’s disease. PLoS One 7(1):e30525PubMedCentralPubMedCrossRef

Titel: Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature
Publikationsdatum: 01.12.2014
Erschienen in: Journal of Neural Transmission / Ausgabe 12/2014
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-014-1226-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Does CSF p-tau₁₈₁ help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Restless legs syndrome in multiple system atrophy

Information handling by the brain: proposal of a new “paradigm” involving the roamer type of volume transmission and the tunneling nanotube type of wiring transmission

A reappraisal of Fe(III) adsorption by melanin

Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss

Characteristics and occurrence of speech impairment in Huntington’s disease: possible influence of antipsychotic medication

Complex molecular regulation of tyrosine hydroxylase

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie